الفهرس | Only 14 pages are availabe for public view |
Abstract Nephrotic syndrome is a disease characterized by proteinuria, hypoalbuminemia, hypercholesterolemia and edema. The nephrotic syndrome is usually involving children between ages of 2 – 10 years. Primary nephrotic syndrome is more common in children less than six years of age (80% of cases) while secondary nephrotic syndrome predominates for patients older than six years old. ACEIs and ARBs are increasingly being used for non specific reduction of nephrotic range proteinuria. These agents reduce proteinuria by decreasing the transcapillary glomerular hydrostatic pressure by altering glomerular permeability. The present study was conducted in Abo El Reish pediatric hospital and Beni Suef university hospital, aiming to study the role of ACE-Is and ARBs in reduction of proteinuria. The study was designed as studied cases and control cases, each group included 20 nephrotic children cases was collected randomly. 206 ENGLISH SUMMARY Study group was treated with combination therapy of captopril and valsartan in addition to prednisolone and control group treated with captopril and prednisolone only. Both studied and control cases were subjected to general examination including blood pressure, clinical examination including edema and laboratory investigations including serum albumin, serum cholesterol, albumin in urine and P/C ratio. We thus initiated this study to evaluate the effect of (ACEIs) plus (ARBs) in combination therapy on decreasing proteinuria in children with steroid resistant and steroid dependent nephrotic syndrome. The results of our study showed that studied cases that were treated with combination therapy led to reduction of proteinuria and decreasing of corticosteroid doses and avoid its side effects as weight and hypertension. Also this study showed that capsule dosage form was rapidely absorbed and more bioavailable than tablet dosage form in treatment of nephrotic children patients. 207 |